JP2017501715A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501715A5
JP2017501715A5 JP2016541634A JP2016541634A JP2017501715A5 JP 2017501715 A5 JP2017501715 A5 JP 2017501715A5 JP 2016541634 A JP2016541634 A JP 2016541634A JP 2016541634 A JP2016541634 A JP 2016541634A JP 2017501715 A5 JP2017501715 A5 JP 2017501715A5
Authority
JP
Japan
Prior art keywords
domain
endopeptidase
pain
composition
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016541634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501715A (ja
JP6378772B2 (ja
Filing date
Publication date
Priority claimed from US14/244,162 external-priority patent/US9216210B2/en
Application filed filed Critical
Publication of JP2017501715A publication Critical patent/JP2017501715A/ja
Publication of JP2017501715A5 publication Critical patent/JP2017501715A5/ja
Application granted granted Critical
Publication of JP6378772B2 publication Critical patent/JP6378772B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016541634A 2013-12-23 2014-12-19 慢性疼痛のためのマルチプロテアーゼ(multiprotease)治療薬 Expired - Fee Related JP6378772B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361920053P 2013-12-23 2013-12-23
US61/920,053 2013-12-23
US14/244,162 2014-04-03
US14/244,162 US9216210B2 (en) 2013-12-23 2014-04-03 Multiprotease therapeutics for chronic pain
PCT/EP2014/078732 WO2015097087A1 (en) 2013-12-23 2014-12-19 Multiprotease therapeutics for chronic pain

Publications (3)

Publication Number Publication Date
JP2017501715A JP2017501715A (ja) 2017-01-19
JP2017501715A5 true JP2017501715A5 (https=) 2018-02-01
JP6378772B2 JP6378772B2 (ja) 2018-08-22

Family

ID=53398919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016541634A Expired - Fee Related JP6378772B2 (ja) 2013-12-23 2014-12-19 慢性疼痛のためのマルチプロテアーゼ(multiprotease)治療薬

Country Status (13)

Country Link
US (2) US9216210B2 (https=)
EP (1) EP3087089B1 (https=)
JP (1) JP6378772B2 (https=)
KR (1) KR101900582B1 (https=)
CN (2) CN105916875A (https=)
AU (1) AU2014372689B2 (https=)
CA (1) CA2934986C (https=)
DK (1) DK3087089T3 (https=)
ES (1) ES2671493T3 (https=)
PL (1) PL3087089T3 (https=)
PT (1) PT3087089T (https=)
WO (1) WO2015097087A1 (https=)
ZA (1) ZA201605051B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
PT3274364T (pt) * 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
JP7118055B2 (ja) * 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
FR3114739B1 (fr) * 2020-10-06 2022-08-26 Centre Nat Rech Scient Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000066I2 (de) 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US20040126396A1 (en) 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
EP0758900B1 (en) 1994-05-09 2002-04-10 BINDER, William J. Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
JP3523879B2 (ja) 1994-05-31 2004-04-26 アレルガン インコーポレイテッド 輸送タンパク質用クロストリジウム属細菌毒素の修飾
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
ATE251463T1 (de) 1998-04-29 2003-10-15 Allergan Inc Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
ATE348178T1 (de) * 1999-08-25 2007-01-15 Allergan Inc Aktivierbare rekombinante neurotoxine
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
GB0111146D0 (en) 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
CA2501856A1 (en) 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
WO2005035730A2 (en) 2003-10-07 2005-04-21 Allergan, Inc. Dna sequences of the botulinum neurotoxin complex of type a-hall (allergan) strain
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2006011966A1 (en) 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US20060024331A1 (en) 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
WO2006069429A1 (en) 2004-09-30 2006-07-06 Pro-Adn Diagnostic Wnt4 in supporting lymphopoiesis
AU2006227816B2 (en) * 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
GB0610868D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
CN102083451A (zh) * 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
KR20110060903A (ko) 2008-08-29 2011-06-08 메르츠 파마 게엠베하 운트 코. 카가아 지속성이 변경된 클로스트리듐 신경독
KR101923847B1 (ko) 2009-03-13 2018-11-29 알러간, 인코포레이티드 면역 기반 재표적화된 엔도펩티다제 활성 검정
AU2010236613B2 (en) * 2009-04-14 2016-07-07 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
SG181772A1 (en) 2009-12-16 2012-07-30 Allergan Inc Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
EP2650003B1 (en) 2010-05-20 2016-07-27 Allergan, Inc. Degradable clostridial toxins
US20130116794A1 (en) 2010-08-04 2013-05-09 Shaul Shohat Shoulder implant
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US20140177773A1 (en) * 2012-12-20 2014-06-26 Maria Christine KRETZING Control rod drive apparatus utilizing alloys with low to zero cobalt content
US20160051644A1 (en) * 2013-01-16 2016-02-25 Bal Ram Singh Botulinum Chimera Compositions for Axonal Regenerative Therapy During Spinal Cord Injury
US9447405B2 (en) * 2013-03-08 2016-09-20 Wisconsin Alumni Research Foundation Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016180533A1 (en) * 2015-05-12 2016-11-17 Merz Pharma Gmbh & Co. Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect

Similar Documents

Publication Publication Date Title
JP2017501715A5 (https=)
Kluskens et al. Post-translational modification of therapeutic peptides by NisB, the dehydratase of the lantibiotic nisin
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
NZ627372A (en) Clostridium histolyticum enzymes and methods for the use thereof
JP6378772B2 (ja) 慢性疼痛のためのマルチプロテアーゼ(multiprotease)治療薬
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
NZ598351A (en) Il-17 binding compounds and medical uses thereof
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
UA101155C2 (ru) Модифицированный полипептид фактора vii (fvii) и его применение
EP3564259A3 (en) Recognition tags for tgase-mediated conjugation
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
EP2670434A2 (en) Treatment of tauopathies
WO2011160062A3 (en) Compositions and methods for treating inflammatory conditions
UA117349C2 (uk) Одноланцюговий гібридний білок та спосіб лікування, попередження або усунення болю
EP2279244A4 (en) METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
BR112013001611A8 (pt) Método para conjugar um polímero solúvel em água a uma fração de carboidrato oxidado de uma proteína terapêutica, proteína terapêutica modificada, método para formar uma ligação oxima entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo amino-óxi ativo emétodo para formar uma ligação hidrazona entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo hidrazida ativo
EA201491117A1 (ru) НОВЫЕ ПРОТЕАЗЫ ИЗ АКТИНОМИЦЕТА ACTINOALLOMURUS, СПОСОБНЫЕ ГИДРОЛИЗОВАТЬ ГЛЮТЕНОВЫЕ ПЕПТИДЫ И БЕЛКИ ПРИ КИСЛОТНОМ pH
JP2016513082A5 (https=)
PH12014500685B1 (en) Treatment of degenerative joint disease
MX377570B (es) Proteínas de fusión ctla4 para el tratamiento de la diabetes.
MX2018014066A (es) Metodo para purificacion y activacion de la neurotoxina botulinica.
RU2017134724A (ru) Химерные полипептиды